Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection

doi:10.4254/wjh.v14.i6.1053

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4496)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

366

WORD

HTML

2284

Figures (1-1)

218

Tables (1-2)

295

Sum=3248

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

193

Download

308

Sum=501

Publishing Process of This Article

Item

Count

Browse

271

Download

476

Sum=747

Jun 27, 2022 (publication date) through Apr 27, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Jun 27, 2022; 14(6): 1053-1073
Published online Jun 27, 2022. doi: 10.4254/wjh.v14.i6.1053

Open in New Tab Full Size Figure Download Figure

Figure 1 Pathophysiology of hepatitis C virus infection in hepatic and extrahepatic diseases. IR: Insulin resistance; T2DM: Type 2 Diabetes Mellitus; IL-1β: Interleukin-1 beta; TNF-α: Tumor necrosis factor-alpha; RF: Rheumatoid factor; ASMA: Anti-smooth muscle antibody; B cell NHLs: B-cell non-Hodgkin lymphomas.

Citation: Salama II, Raslan HM, Abdel-Latif GA, Salama SI, Sami SM, Shaaban FA, Abdelmohsen AM, Fouad WA. Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection. World J Hepatol 2022; 14(6): 1053-1073
URL: https://www.wjgnet.com/1948-5182/full/v14/i6/1053.htm
DOI: https://dx.doi.org/10.4254/wjh.v14.i6.1053